Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Decline in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 890,908 shares, a decline of 32.4% from the March 15th total of 1,318,064 shares. Approximately 5.1% of the shares of the company are short sold. Based on an average trading volume of 3,378,307 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of Biorestorative Therapies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC raised its holdings in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after purchasing an additional 12,319 shares during the last quarter. DRW Securities LLC bought a new position in shares of Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Finally, Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies in the 3rd quarter worth approximately $152,000. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Stock Performance

Shares of NASDAQ BRTX traded down $0.01 during midday trading on Thursday, reaching $0.25. The stock had a trading volume of 485,618 shares, compared to its average volume of 8,177,697. The firm has a market cap of $6.32 million, a price-to-earnings ratio of -0.16 and a beta of 0.37. The company’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.94. Biorestorative Therapies has a twelve month low of $0.19 and a twelve month high of $2.05.

Biorestorative Therapies (NASDAQ:BRTX) last released its earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.37). Biorestorative Therapies had a negative net margin of 3,956.11% and a negative return on equity of 430.91%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.15 million. Equities analysts forecast that Biorestorative Therapies will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.